Optimizing Fracture Prevention in Patients with Osteoporosis

Article Figures & Data

Table 1. Comparison of Stage A and Stage C Results

Parameter	Stage A Result	Stage C Result	P Value	Cluster-Adjusted P Value
Age, years (mean ± SD)	72.7 ± 10.2	73.4 ± 9.2	.048^*
Female sex	1919/2107 (91.1%)	1698/1814 (93.6%)	.003^{^†}
Fracture of hip, spine, or distal radius (yes)	576/2107 (27.3)	482/1814 (23.8)	.01^{^†}
Diagnosed with osteoporosis	1200/2107 (57.0)	1045/1814 (57.6)	.68^{^†}
Central DXA measurement since age 60	1267/1622 (78.1)	1278/1537 (83.2)	.0003^{^†}	.03
Central DXA measurement ordered or performed	376/569 (66.1)	355/429 (82.8)	<10^{−5^†}	.002
Prescribed pharmacologic therapy	1111/2084 (53.3)	1062/1805 (58.8)	.0005^{^†}	.02
Prescribed calcium and vitamin D	1082/1200 (90.2)	993/1045 (95.0)	.00001^{^†}	.02
Counseling for calcium, vitamin D, and exercise	949/1200 (79.1)	940/1045 (90.0)	<10^{−5^†}	<.0001